VERICEL CORPORATION (VCEL) Operating Margin
- Operating margin · 12 months: Value 5.95%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | 5.95% | Operating income / revenue. Period ending 2026-06-30. $18.23M ÷ $306.30M × 100 ≈ 5.95% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | 18.23M USD | Operating Income (Loss) |
| Revenue | 306.30M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | 77.92M USD | Cost of Goods and Services Sold |
| Research and development | 29.17M USD | Research and Development Expense |
| Selling, general and administration | 180.98M USD | Selling, General and Administrative Expense |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $18.23M | $306.30M | $77.92M | $29.17M | $180.98M | 5.95% |
| 2026-03-31 | $15.77M | $292.09M | $73.49M | $28.41M | $174.41M | 5.40% |
| 2025-12-31 | $11.04M | $276.26M | $70.66M | $27.56M | $166.99M | 4.00% |
| 2025-09-30 | $7.11M | $258.72M | $67.75M | $25.23M | $158.63M | 2.75% |
| 2025-06-30 | $1.19M | $249.12M | $66.08M | $25.01M | $156.84M | 0.48% |
| 2025-03-31 | $-2.81M | $238.54M | $65.52M | $25.64M | $150.19M | -1.18% |
| 2024-12-31 | $4.52M | $237.22M | $65.12M | $24.80M | $142.79M | 1.90% |
| 2024-09-30 | $-1.23M | $226.84M | $64.73M | $24.77M | $138.57M | -0.54% |
| 2024-06-30 | $-3.82M | $214.52M | $63.45M | $24.36M | $130.53M | -1.78% |
| 2024-03-31 | $-3.75M | $207.78M | $63.37M | $22.25M | $125.91M | -1.81% |
| 2023-12-31 | $-6.46M | $197.52M | $61.94M | $21.04M | $121.00M | -3.27% |
| 2023-09-30 | $-13.11M | $185.21M | $59.90M | $21.39M | $117.04M | -7.08% |
| 2023-06-30 | $-14.84M | $177.96M | $58.24M | $20.76M | $114.03M | -8.34% |
| 2023-03-31 | $-17.96M | $168.86M | $56.45M | $20.30M | $110.52M | -10.64% |
| 2022-12-31 | $-17.06M | $163.70M | $54.58M | $19.94M | $106.90M | -10.42% |
| 2022-09-30 | $-19.00M | $158.05M | $53.69M | $18.62M | $105.95M | -12.02% |
| 2022-06-30 | $-17.18M | $153.45M | $52.78M | $17.86M | $101.75M | -11.19% |
| 2022-03-31 | $-11.82M | $155.30M | $51.20M | $17.52M | $100.80M | -7.61% |
| 2021-12-31 | $-7.85M | $153.07M | $50.16M | $16.29M | $97.59M | -5.13% |
| 2021-09-30 | $294.00K | $150.28M | $48.18M | $15.48M | $89.86M | 0.20% |
| 2021-06-30 | $8.77M | $147.58M | $45.56M | $14.11M | $83.13M | 5.94% |
| 2021-03-31 | $4.14M | $128.92M | $41.61M | $12.89M | $73.43M | 3.21% |
| 2020-12-31 | $2.37M | $121.97M | $39.95M | $13.02M | $68.84M | 1.94% |
| 2020-09-30 | $-707.00K | $117.10M | $38.95M | $13.12M | $66.97M | -0.60% |
| 2020-06-30 | $-1.13M | $116.58M | $38.49M | $13.30M | $65.92M | -0.97% |
| 2020-03-31 | $-12.97M | $122.72M | $38.85M | $31.15M | $65.69M | -10.57% |
| 2019-12-31 | $-11.25M | $117.85M | $37.57M | $30.39M | $61.14M | -9.55% |
| 2019-09-30 | $-14.47M | $109.80M | (m) | $30.19M | $58.45M | -13.18% |
| 2019-06-30 | $-18.90M | $101.78M | (m) | $30.21M | $56.04M | -18.57% |
| 2019-03-31 | $-2.94M | $72.85M | (m) | $12.88M | $51.57M | -4.04% |
| 2018-12-31 | $-3.91M | $90.86M | $32.16M | $13.60M | $49.01M | -4.30% |
| 2018-09-30 | $-8.71M | $82.87M | (m) | $14.17M | $45.50M | -10.51% |
| 2018-06-30 | $-11.41M | $74.65M | (m) | $13.97M | $41.11M | -15.28% |
| 2018-03-31 | $-9.68M | $72.59M | (m) | $13.21M | $38.16M | -13.34% |
| 2017-12-31 | $-14.98M | $63.92M | (m) | $12.94M | $35.61M | -23.44% |
| 2017-09-30 | $-22.06M | (m) | (m) | $13.62M | $33.35M | (m) |
| 2017-06-30 | $-24.41M | (m) | (m) | $14.14M | $32.18M | (m) |
| 2017-03-31 | $-26.88M | (m) | (m) | $15.23M | $29.79M | (m) |
| 2016-12-31 | $-19.25M | $54.38M | (m) | $15.29M | $27.39M | -35.39% |
| 2016-09-30 | $-18.31M | $53.28M | (m) | $18.44M | $25.21M | -34.37% |
| 2016-06-30 | $-16.81M | $53.66M | (m) | $18.74M | $23.87M | -31.33% |
| 2016-03-31 | $-14.09M | $54.43M | (m) | $18.05M | $23.01M | -25.89% |
| 2015-12-31 | $-16.67M | $51.17M | (m) | $18.89M | $22.48M | -32.58% |
| 2015-09-30 | $-14.06M | $50.45M | (m) | $17.28M | $21.24M | -27.87% |
| 2015-06-30 | $-17.20M | $48.80M | (m) | $21.37M | $19.88M | -35.25% |
| 2015-03-31 | $-23.46M | $39.65M | (m) | $22.37M | $17.88M | -59.18% |
| 2014-12-31 | $-23.53M | $28.80M | (m) | $21.26M | $13.77M | -81.73% |
| 2014-09-30 | $-26.11M | $14.10M | (m) | $18.79M | $10.88M | -185.22% |
| 2014-06-30 | $-21.73M | $4.44M | (m) | $13.53M | $7.64M | -489.44% |
| 2014-03-31 | $-18.44M | (m) | (m) | $12.84M | $5.62M | (m) |
| 2013-12-31 | $-20.96M | $19.00K | (m) | $15.10M | $5.88M | -110336.84% |
| 2013-09-30 | $-23.66M | $30.00K | (m) | $17.80M | $5.88M | -78856.67% |
| 2013-06-30 | $-28.30M | $30.00K | (m) | $21.37M | $6.95M | -94336.67% |
| 2013-03-31 | $-32.37M | $27.00K | (m) | $24.77M | $7.62M | -119877.78% |
| 2012-12-31 | $-33.76M | $21.00K | (m) | $26.02M | $7.75M | -160761.90% |
| 2012-09-30 | $-33.98M | $2.00K | (m) | $25.92M | $8.06M | -1698850.00% |
| 2012-06-30 | $-33.13M | $11.00K | (m) | $25.52M | $7.62M | -301190.91% |
| 2012-03-31 | $-31.34M | $11.00K | (m) | $23.75M | $7.59M | -284890.91% |
| 2011-12-31 | $-29.04M | $18.00K | (m) | $21.33M | $7.72M | -161333.33% |
| 2011-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-03-31 | $-23.02M | (m) | (m) | $16.60M | $6.68M | (m) |
| 2010-12-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-06-30 | $-16.17M | $182.00K | (m) | $11.29M | $4.95M | -8884.07% |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |